



UM | NIST
INSTITUTE FOR
BIOSCIENCE &
BIOTECHNOLOGY
RESEARCH

The use of small angle X-ray scattering for studying excipient modulated physical stability and viscosity of monoclonal antibody formulations


Amy Y. Xu, Maria M. Castellanos, Kevin Mattison, Susan Krueger, Joseph E. Curtis

*NIST Center for Neutron Research, National Institute of Standards and Technology
Institute for Bioscience and Biotechnology Research, University of Maryland*

HOS2019, San Mateo, California. April 8th 2019

Challenges of monoclonal antibody (mAb) formulation

- High concentration is required to achieve therapeutic dosage
- High concentration leads to increased non-specific **protein-protein interactions (PPI)** that could lead to self-association and solution viscosity
- Excipients are used to improve protein colloidal stability (tendency to remain monomeric form)
- Selection of excipients involves laborious empirical screening due to limited knowledge of the effects of excipients on PPI



Commonly used excipients*

Aims of this study



- To characterize the effects of excipients on a particular monoclonal antibody (NISTmAb)
- To evaluate different techniques for studying excipient modulated PPI in concentrated mAb formulations
 - *Physical stability:*
Dynamic Light Scattering (DLS) vs Small Angle X-ray Scattering (SAXS)
 - *Solution viscosity:*
DLS, SAXS (predicted) vs Viscosity measurements (experimental)


Excipient Class	Excipients	Buffer	Ionic Concentration (mM)	pH
Sugars	300 mM Glucose	25 mM Histidine	12.5	6
	300 mM Sucrose	25 mM Histidine	12.5	6
	300 mM Trehalose	25 mM Histidine	12.5	6
	300 mM Mannitol	25 mM Histidine	12.5	6
Amino Acids	171 mM Arginine	25 mM Histidine	196	6
	200 mM Proline	25 mM Histidine	12.5	6
	200 mM Glycine	25 mM Histidine	12.5	6
	200 mM Alanine	25 mM Histidine	12.5	6
Non-ionic Surfactants	0.06 mM Polysorbate 20	25 mM Histidine	12.5	6
	0.12 mM Polysorbate 80	25 mM Histidine	12.5	6
Salts	150 mM NH ₄ Cl	25 mM Histidine	162.5	6
	150 mM Na ₂ SO ₄	25 mM Histidine	312.5	6
	150 mM NaCl	25 mM Histidine	162.5	6
	150 mM NaClO ₄	25 mM Histidine	162.5	6
pH	-	67 mM Phosphate	82.8	6
	-	67 mM Phosphate	148.3	7
	-	67 mM Phosphate	196	8

mAbs in 25mM histidine buffer (without excipient) is used as control sample

NIST monoclonal antibody reference material (NISTmAb)




- First mAb (IgG1) reference material, representative of the largest class of biological therapeutics
- Standard reference material for analytical characterization of biopharmaceutical products, facilitates the assessment of existing analytical methods and promotes faster adoption of new technologies
- Used as representative mAb for this study



3D structure of NISTmAb*

Small Angle Scattering



The scattered intensity is expressed as:


$$I(\mathbf{q}) = (\Delta\rho^2 \phi V) * P(\mathbf{q}) * S(\mathbf{q})$$

Where $\Delta\rho$ is the difference in scattering length density, ϕ is the volume fraction, V is the volume of the scattered objects, $P(\mathbf{q})$ is the **form factor** and $S(\mathbf{q})$ is the **structure factor**

Small Angle Scattering


Form Factor $P(q)$

- Measured from dilute solution, where intermolecular interactions are negligible
- Contains information on the size and shape of scattering objects




Structure Factor $P(q)$

- Arise due to intermolecular interactions with increasing concentration
- Contains information on the relative position/spatial correlation of scattering objects



Protein colloidal stability: DLS vs SAXS



- **Dynamic light scattering (DLS)**

- Measured at low concentrations, (<10mg/ml), but used to predict properties of concentrated formulations


- Interaction parameter k_D is obtained from DLS measurements:

$$k_D = 2B_{22}M_W - (k_f + 2v)$$

Where $B_{22}M_W$ is the thermodynamic component,
 $k_f + 2v$ is the hydrodynamic component

- $k_D > -8 \text{ ml/g}^*$: **Net Repulsive PPI**
- $k_D < -8 \text{ ml/g}^*$: **Net Attractive PPI**

Protein colloidal stability: DLS vs SAXS



- **Dynamic light scattering (DLS)**


- Measured at low concentrations, (<10mg/ml), but used to predict properties of concentrated formulations
- 2nd virial coefficient B_{22} is obtained from DLS measurements:

$$\frac{KC}{R_{\theta}} = \frac{1}{M_W} + 2B_{22}C$$

Where K is an optical constant, R_{θ} is the Rayleigh ratio of scattered to incident light intensity, M_w is the weight average molecular weight

- **$B_{22} > 0 \text{ mol ml/g}^2$: Net Repulsive PPI**
- **$B_{22} < 0 \text{ mol ml/g}^2$: Net Attractive PPI**

Protein colloidal stability: DLS vs SAXS



SAXS spectra and $S(q)$ measured from NISTmAb in Alanine solution as a function of protein concentration


- **Small Angle X-ray Scattering(SAXS)**

- Measured at both low and high concentrations

$$I(q) \propto P(q)S(q)$$

$P(q)$ is measured from dilute solutions
 $S(q)$ is measured from concentrated solutions

Protein colloidal stability: DLS vs SAXS



- **Small Angle X-ray Scattering(SAXS)**



- $S(q)$ at $q \rightarrow 0$, i.e. $S(0)$ is obtained from fitting $S(q)$ profile, it is used to study nature of PPI

$S(0) < 1$: Net Repulsive PPI
 $S(0) > 1$: Net Attractive PPI

SAXS spectra and $S(q)$ measured from NISTmAb in Alanine solution as a function of protein concentration


Comparison between k_D / B_{22} and $S(0)$

- $S(0)$ value less than 1 was measured from all excipient conditions, suggesting the net PPI was of repulsive nature
- Close agreement was found between $S(0)$ and k_D values



Analysis of $S(q)$ reveals various energetic components towards the net PPI


- *Compared to DLS, more information on PPI is revealed by SAXS*




Different contributors toward net PPI can be resolved by fitting $S(q)$ profile to different models

Analysis of $S(q)$ reveals various energetic components towards the net PPI



- Compared to DLS, more information on PPI is revealed by SAXS



Excluded Volume Effect
(hard sphere model)



Hayter-Penfold model




Additional repulsive forces
lead to smaller $S(0)$


Different contributors toward net PPI can be resolved
by fitting $S(q)$ profile to different models

Analysis of $S(q)$ reveals various energetic components towards the net PPI

- Compared to DLS, more information on PPI is revealed by SAXS




Different contributors toward net PPI can be resolved by fitting $S(q)$ profile to different models



Additional attractive forces lead to larger $S(0)$




Analysis of $S(q)$ reveals various energetic components towards the net PPI

- $S(0)_{\text{exp}}/S(0)_{\text{HS}}$
 - < 1: improved colloidal stability
 - > 1: reduced colloidal stability
- Further analysis of $S(q)$ reveals the presence of attractive intermolecular interactions even though the net PPI is repulsive



Solution Viscosity: Predicted vs Experimental results

- Measurements were made to obtain the viscosity (η) of concentrated NISTmAb formulations (170mg/ml), whereas k_D , B_{22} and $S(0)$ were used to predict the viscosity (η) of concentrated NISTmAb formulations



Shaded area highlights samples from which a decrease in k_D/B_{22} or an increase in $S(0)$ is correlated with an increase in η , and vice versa

Conclusions



- NISTmAb is colloidally stable in all of the examined excipient conditions. Although the net PPI is repulsive, elevated solution viscosity was measured with the presence of excipients
- The close agreement between k_D and $S(0)$ results suggests DLS could be used to provide reliable information on the colloidal stability of mAbs in concentrated formulations.
- Detailed analysis of $S(q)$ reveals various energetic components towards the net PPI, hence provides valuable insights in guiding the excipient selections
- B_{22} and $S(0)$ appeared to be better viscosity predictors than k_D . Disagreement between predicted and measured results suggests other factors apart from PPI contribute to the bulk rheological properties of concentrated protein solutions.

Acknowledgements



NIST Center for Neutron Research

- *Dr Joseph Curtis*
- *Dr Susan Krueger*



GlaxoSmithKline

- *Dr Maria Castellanos*



UM | NIST
INSTITUTE FOR
BIOSCIENCE &
BIOTECHNOLOGY
RESEARCH

University of Maryland

Institute for Bioscience and Biotechnology Research

- *Dr John Schiel*
- *Dr Robert Brinson*
- *Dr Alexander Grishaev*
- *Dr Mihaela Mihailescu*
- *Dr John Marino*



Malvern-Panalytical

- *Dr Kevin Mattison*